Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Easing the PPE Strain During the Pandemic

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe. Even before…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Easing the PPE Strain During the Pandemic

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

During the early days of the pandemic, one of the healthcare community’s challenges was a critical lack of PPE to fight the coronavirus. Ryan Madewell, Director of Environmental Services at Hunt Regional Healthcare for Vanguard Resources, spoke about this problem and how Surfacide’s UV-C solutions helped keep front-line workers and patients safe.

Even before hospitals began to fill up with coronavirus-infected patients, Madewell said the challenge was always how to get more PPE to prepare for those patients.

“We began researching how we were going to be able to get through if we weren’t able to get more PPE or if there was a limited supply, so we landed on UV light. We already had the Surfacide. We’ve been happy with our Helios system for the past seven years. Finding another use for it was great,” he said.

Due to the infectious nature of the virus, Madewell said the situation provided a dual challenge. While never transitioning entirely away from patient safety, it became essential to protect healthcare workers and employees from the virus.

“The fact [was] we had a limited amount of specifically N95s, but disinfectants [also] became hard to come by,” Madewell said. “We had to make some changes and readdress what our processes were going to be, and we made sure everybody stayed safe and had what they needed to do their job.”

When the CDC provided guidance saying UV-C could be used in an emergency to reprocess N95 respirators, and Madewell and his team put a plan together to use Surfacide.

“Not long after we started trial runs, and began reprocessing when it was necessary,” Madewell said. “And we’ve been doing it ever since.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512